Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
The abstract describes Zeno’s activity in preclinical models representing different tumor types expressing high neuregulin 1 (NRG1) levels.
- The abstract describes Zeno’s activity in preclinical models representing different tumor types expressing high neuregulin 1 (NRG1) levels.
- High NRG1 expression is associated with poorer prognosis in certain cancers and resistance to standard therapies.
- The anti-tumor efficacy of Zeno in vivo against a panel of 28 patient-derived xenograft (PDX) models representing different tumor types was examined.
- Title: Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective in cancer models with high NRG1 expression.